Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation-Reference-Cited by-全球学者库

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

Published:2023-03-14 Issue:7 Volume:136 Page:848-850
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Mao Shiqi¹,Luo Libo¹,Yang Shuo¹,Wang Yan¹,Zhou Fei¹,Yu Jia¹,Chen Bin¹,Gao Guanghui¹,Li Xuefei²,Zhao Chao²,Cheng Lei²,Liu Yiwei¹,Wang Wanying¹,Jia Keyi¹,Shao Chuchu¹,Liu Xinyu¹,Chen Xiaoxia¹,Su Chunxia¹,Zhou Caicun¹,Wu Fengying¹,Ren Shengxiang¹

Affiliation:

1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China

2. Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference8 articles.

1. The force of HER2 – A druggable target in NSCLC?;Jebbink;Cancer Treat Rev,2020

2. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib;Wang;Ann Oncol,2019

3. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study;Zhou;J Clin Oncol,2020

4. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC;Mao;Cancer Immunol Immunother,2022

5. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment;Friedlaender;Nat Rev Clin Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrotinib;Reactions Weekly;2023-08-26